Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 8, 2017
Reporting Period: Quarter ended June 30, 2017
Context: The filing serves to announce the Company's financial results for the second quarter of 2017. The Company is designated as an emerging growth company.
Key Financial Metrics
The provided Form 8-K text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It explicitly states that the full financial results are contained in a press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the text of this filing.
Material Changes
No material changes or comparative financial data versus the prior period are detailed in the text of this filing. The document acts solely as a notification of the results announcement.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release issued on August 8, 2017, containing the results, but does not include the text of that commentary.
Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that Section, nor is it incorporated by reference in other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 8, 2017) for specific revenue, net loss, and cash position figures.
- Verify the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Confirm the exact date of the press release to ensure alignment with the reporting period (Q2 2017).
- Check subsequent filings for any updates to the financial data referenced in this 8-K.